You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Bulk Pharmaceutical API Sources for fludeoxyglucose f-18


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for fludeoxyglucose f-18

Vendor Vendor Homepage Vendor Sku API Url
NovoSeek ⤷  Get Started Free 450503 ⤷  Get Started Free
ABI Chem ⤷  Get Started Free AC1L9OYT ⤷  Get Started Free
AKos Consulting & Solutions ⤷  Get Started Free AKOS006272016 ⤷  Get Started Free
BOC Sciences ⤷  Get Started Free 105851-17-0 ⤷  Get Started Free
OChem ⤷  Get Started Free 22890 ⤷  Get Started Free
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for: Fludeoxyglucose F-18

Last updated: July 29, 2025

Introduction

Fludeoxyglucose F-18 (FDG) is a radiopharmaceutical extensively utilized in positron emission tomography (PET) imaging, primarily for oncology, cardiology, and neurology diagnostics. Its efficacy hinges on high-quality radiotracer production, which directly depends on the availability of bulk F-18 API. The source, quality, and regulatory compliance of F-18 API suppliers are critical for clinical and commercial applications. This report provides an in-depth analysis of global sources for bulk F-18 API, focusing on key manufacturers, manufacturing processes, quality standards, and market dynamics.


Overview of F-18 API Production

F-18 is a radioactive isotope with a half-life of approximately 110 minutes. It is produced through cyclotron irradiation of enriched oxygen-18 (^18O) water, facilitating the formation of F-18 fluoride ion. The synthesis process involves complex steps to ensure radiochemical purity and specific activity suitable for medical PET imaging. Because F-18 is produced on-site or at dedicated radiopharmacies, suppliers typically produce high-purity ^18O water, which serves as the precursor for F-18 F-18 fluoride production.


Major Suppliers of F-18 API

1. Cyclotron Facilities and OEMs

The production of F-18 API predominantly occurs at dedicated cyclotron facilities and OEMs (Original Equipment Manufacturers) who supply the necessary targetry and radiochemical synthesis modules. These facilities often manufacture and supply ^18O-enriched water as the primary raw material. Such suppliers are classified as bulk API providers because the ^18O water is a crucial precursor in the F-18 manufacturing process.

  • Siemens Healthineers
    Siemens operates multiple cyclotron and radiochemistry units globally, producing F-18 tracers within their clinical and research centers. They supply ^18O water and proprietary synthesis modules to hospitals and radiopharmacies.

  • GE Healthcare (Amersham)
    With extensive infrastructure in North America and Europe, GE supplies ^18O-enriched water and F-18 synthesis kits, alongside cyclotron bundles.

  • IBA Molecular (MeI LLC)
    A prominent OEM offering cyclotron systems and targetry for F-18 production, including specified ^18O water.

2. Standalone ^18O Enriched Water Suppliers

Since F-18 production relies heavily on high-purity ^18O water, these suppliers represent the core bulk API providers for F-18 generators.

  • IsoTherapeutics
    Offers high-purity, pharmaceutical-grade ^18O-enriched water specifically designed for radiopharmaceutical synthesis, including F-18.

  • Rotem Industries
    A leading Israeli manufacturer supplying ^18O-enriched water with high isotopic enrichment (≥ 99%) suitable for medical isotope production.

  • PerkinElmer
    Provides high-purity ^18O water as part of its radiochemistry solutions portfolio, supporting F-18 synthesis.

  • Nordion (Canada)
    Supplies ^18O water and related radiochemical reagents with a focus on GMP compliance.

3. Regional and Contract Manufacturers

In addition to OEMs and large suppliers, regional vendors and contract manufacturing organizations (CMOs) support localized F-18 radiotracer production.

  • Bracco Imaging
    Engages in manufacturing and supplying radiopharmaceutical reagents, including raw materials for F-18 synthesis, with operational facilities across Europe and the U.S.

  • Eckert & Ziegler
    Offers targetry and cyclotron solutions, including the supply of ^18O water.


Supply Chain and Market Dynamics

The supply chain for F-18 API components, especially ^18O-enriched water, is characterized by tightly controlled manufacturing parameters, rigorous regulatory standards (e.g., European Pharmacopoeia, USP), and logistical constraints tied to the short half-life of F-18.

  • Manufacturing Constraints
    The production of high isotopic purity ^18O water requires specialized enrichment centrifuge technology, with costs driven by the isotopic separation process.

  • Regulatory Landscape
    Suppliers must comply with GMP standards, and documentation must be available to support traceability, batch consistency, and safety profiles as per pharmacopeial requirements.

  • Market Trends
    Growing demand in oncology imaging is expanding the need for reliable, high-quality F-18 API sources. The increased deployment of cyclotrons in hospitals worldwide is creating a decentralized production landscape, emphasizing regional suppliers for timely delivery.


Quality & Regulatory Standards

Suppliers of F-18 API, especially ^18O water, must adhere to strict regulatory frameworks:

  • Pharmacopoeial Standards

    • European Pharmacopoeia monograph for "^18O-enriched water for injections"
    • USP <821> Radiopharmaceuticals
  • GMP Certification
    Ensures purity, sterility, and reproducibility across batches.

  • Radiochemical Purity & Specific Activity
    Suppliers need to guarantee a high radiochemical purity (> 99%) and appropriate specific activity compatible with clinical imaging needs.


Emerging and Future Trends

  • In-House Production
    Hospitals and radiopharmacies increasingly adopt cyclotron systems, reducing dependence on external API suppliers for ^18O water.

  • Global Expansion
    Countries such as China and India are investing in cyclotron infrastructure to develop local F-18 production capabilities, thus diversifying supply sources.

  • Supplier Consolidation and Competition
    Ongoing consolidation among OEMs and suppliers may influence prices and supply chain robustness.


Key Challenges

  • Logistical Constraints
    The short half-life necessitates rapid distribution, complicating supply chain logistics.

  • High Production Costs
    Isotope enrichment remains costly, and capacity expansion is capital-intensive.

  • Regulatory Barriers
    Varying regional standards can complicate global procurement strategies.


Conclusion

The supply ecosystem for bulk F-18 API, especially ^18O-enriched water, is predominantly composed of specialized cyclotron facilities, OEM providers, and regional suppliers adhering to strict pharmaceutical standards. As demand for PET imaging grows, the landscape is evolving towards increased decentralization, regional production sites, and integrated supply chains. Ensuring reliable, high-quality sources remains critical for the continuity of clinical diagnostic services utilizing F-18.


Key Takeaways

  • The primary bulk API source for F-18 is ^18O-enriched water supplied by specialized manufacturers like Rotem Industries, PerkinElmer, and IsoTherapeutics.
  • Production of F-18 API depends on high isotopic enrichment, GMP standards, and advanced cyclotron technology.
  • Regional suppliers and in-house cyclotron setups are reducing reliance on centralized providers, promoting supply resilience.
  • Stringent regulatory standards and logistical challenges influence supplier selection and procurement strategies.
  • Market expansion and technological advances are anticipated to diversify supply sources, but capacity and regulatory compliance remain critical.

FAQs

1. What is the main raw material used in F-18 production?
The core raw material is high-purity ^18O-enriched water, which serves as the target for cyclotron irradiation to produce F-18 fluoride.

2. Who are the leading suppliers of ^18O-enriched water globally?
Rotem Industries, PerkinElmer, and IsoTherapeutics are among the prominent suppliers, providing high-purity ^18O water compliant with pharmaceutical standards.

3. How does the short half-life of F-18 influence supply sources?
The approximately 110-minute half-life necessitates rapid production and distribution, favoring regional suppliers and in-house cyclotron facilities for timely access.

4. Are there regional differences in F-18 API sourcing?
Yes, developed countries tend to have more regional suppliers and infrastructure, while emerging markets are investing in local cyclotron setups to reduce dependency.

5. What regulatory standards govern F-18 API quality?
Standards from the European Pharmacopoeia, USP, and applicable regional guidelines set quality, purity, and safety benchmarks, mandating GMP compliance for suppliers.


References

[1] European Pharmacopoeia Monograph on ^18O-enriched water.
[2] USP <821> Radiopharmaceuticals.
[3] IAEA Cyclotron and Radiopharmaceutical Production Guidelines.
[4] Siemens Healthineers, “F-18 Production & Supply Chain”.
[5] Rotem Industries, “High-Purity ^18O Water for Medical Use”.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.